Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer

Asan Medical Center750 enrolled

Overview

To develop a robust prediction model to predict the occurrence of grade 3-4 neutropenia induced by adjuvant paclitaxel/carboplatin chemotherapy in patients with epithelial ovarian cancer and to validate this model.

Study Type

OBSERVATIONAL

Enrollment

750

Conditions

Epithelial Ovarian Cancer

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with FIGO stage I-IV epithelial ovarian cancer after staging or debulking surgery * Patients who is planned to receive (prospective cohort) ro who received (retrospective cohort) adjuvant chemotherapy with paclitaxel and carboplatin * Patients who have signed approved informed consent Exclusion Criteria: * Uncontrolled medical disease * Active infectious disease * Previous pelvic radiation therapy * Previous chemotherapy (prospective cohort) * Patients with disease which can cause neutropenia * Patients who will receive other targeted therapy or immunotherapy during adjuvant therapy (prospective cohort). * Pregnant or lactating woman

Locations (1)

Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Risk prediction model for grade 3-4 chemotherapy induced neutropenia

Time frame: 1 year

Secondary Outcomes

The association between mannose-binding lectin 2 gene SNP and neutropenia

Time frame: 1 year

Central Contacts

Jeong-Yeol Park, M.D., Ph.D.

CONTACT

82-2-3010-3646 catgut1-0@hanmail.net

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.